Analysts: Vitamin Shoppe Lacks Catalysts and 3 More Research Notes to Check Out
Vitamin Shoppe (NYSE:VSI): Credit Suisse has downgraded Vitamin Shoppe to Neutral from Outperform due to top-line deceleration and a lack of catalysts for next year. The firm has lowered its price target, as well, to $46 from $55.
EV Energy (NASDAQ:EVEP): Oppenheimer has downgraded EV Energy to Perform from Outperform after assuming coverage of the stock. The firm cited the disappointing size of the company’s first Utica transaction and its equity needs.
Synergy Pharmaceuticals (NASDAQ:SGYP): Cantor has reduced its price target to $11 from $15 on Synergy as the firm has begun valuing the company as a potential takeover target. It believes that larger drug companies have become more aware of the attractiveness of the IBS market and keeps a Buy rating on Synergy.
Merge Healthcare (NASDAQ:MRGE): RW Baird believes that the selloff of Merge Healthcare following its second-quarter results is overdone, citing a sum-of-the-parts analysis. The firm noted that management raised expectations with upbeat selling commentary but client spending slowed. The shares remain Outperform rated but the price target was lowered to $4 from $7.